Neurological disease biotech Longboard Pharmaceuticals sets terms for $75 million IPO

Longboard Pharmaceuticals, a Phase 1 biotech formed by Arena Pharmaceuticals developing medicines for neurological diseases, announced terms for its IPO on Monday.

The San Diego, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 toRead More